CLAIMS

1. A compound selected from the group consisting of

compounds of formula (I):



(I)

wherein

R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy and heterocyclyl, or R^3 and R^4 form together a $-CH_2-CH_2-CH_2-$ group;

with the proviso that at least one of R^1, R^2, R^3 and R^4 is not hydrogen;

R^5 is hydrogen, alkyl or cycloalkyl;

R^6 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl; and

R^7 is hydrogen, halogen, alkyl, cycloalkyl, hydroxyalkyl, carboxyalkyl, carbamoylalkyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, formyl, alkylcarbonyl, alkoxy or alkylthio;

pharmaceutically acceptable salts of compounds of formula (I);
pharmaceutically acceptable solvates of compounds of formula (I); and
pharmaceutically acceptable esters of compounds of formula (I).

2. The compound according to claim 1, wherein
R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino,

nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy or heterocyclyl;
with the proviso that at least one of the moieties R^1, R^2, R^3 and R^4 is not hydrogen; and
R^6 is alkyl or cycloalkyl.

3. The compound according to claim 1, wherein
R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy or heterocyclyl;
with the proviso that at least one of the moieties R^1, R^2, R^3 and R^4 is not hydrogen; and
R^6 is alkyl or hydroxyalkyl.

4. The compound according to claim 3, wherein R^6 is methyl.

5. The compound according to claim 3, wherein R^5 is hydrogen.

6. The compound according to claim 3, wherein R^7 is hydrogen, alkyl or alkoxy.

7. The compound according to claim 6, wherein R^7 is hydrogen or methyl.

8. The compound according to claim 1, wherein R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, alkyl, haloalkyl, haloalkoxy and cyano or R^3 and R^4 form together a $-CH_2-CH_2-CH_2-$ group.

9. The compound according to claim 8, wherein R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, alkyl, trifluoromethyl and cyano.

10. The compound according to claim 9, wherein R^1, R^2, R^3 and R^4 are independently selected from hydrogen, methyl, ethyl, fluoro, chloro, cyano and trifluoromethyl.

11. The compound according to claim 10, wherein R^4 is methyl or ethyl and R^1, R^2 and R^3 are hydrogen.

12. The compound according to claim 10, wherein R^4 is fluoro, cyano or trifluoromethyl and R^1, R^2 and R^3 are independently selected from hydrogen or methyl.

13. A compound selected from the group consisting of

compounds of formula (I):



(I)

wherein

R^1, R^2, R^3 and R^4 are independently selected from hydrogen, methyl, ethyl, fluoro, chloro, cyano and trifluoromethyl, with the proviso that at least one of R^1, R^2, R^3 and R^4 is not hydrogen;

R^5 is methyl;

R^6 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl; and

R^7 is hydrogen or methyl;

pharmaceutically acceptable salts of compounds of formula (I);
pharmaceutically acceptable solvates of compounds of formula (I); and
pharmaceutically acceptable esters of compounds of formula (I).

14. The compound according to claim 13, selected from the group consisting of (R)-6-ethyl-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole, pharmaceutically acceptable salts thereof and pharmaceutically acceptable solvates thereof.

15. The compound according to claim 14, which is (R)-6-ethyl-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.

16. The compound according to claim 13, selected from the group consisting of (R)-4,6-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

17. The compound according to claim 16, which is (R)-4,6-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.

18. The compound according to claim 13, selected from the group consisting of (R)-7-chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

19. The compound according to claim 18, which is (R)-7-chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.

20. The compound according to claim 13, selected from the group consisting of (R)-4-methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

21. The compound according to claim 20, which is (R)-4-methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.

22. The compound according to claim 13, selected from the group consisting of (R)- 6-ethyl-8-fluoro-4-methyl -1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

23. The compound according to claim 22, which is (R)- 6-ethyl-8-fluoro-4-methyl -1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.

24. The compound according to claim 13, selected from the group consisting of (R)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

25. The compound according to claim 24, which is (R)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.

26. The compound according to claim 13, selected from the group consisting of (R)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

27. The compound according to claim 26, which is (R)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride.

28. The compound according to claim 13, selected from the group consisting of (R)-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole-6-carbonitrile hydrochloride, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

29. The compound according to claim 28, which is (R)-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole-6-carbonitrile hydrochloride.

30. The compound according to claim 13, selected from the group consisting of (R)-4,6,10-trimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole oxalate, pharmaceutically acceptable salts thereof and pharmaceutically acceptably solvates thereof.

31. The compound according to claim 30, which is (R)-4,6,10-trimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole oxalate.

32. A compound according to claim 1, selected from the group consisting of (R)-6-thienyl-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;

(R)-4,6-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
(R)-7-chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
(R)-4-methyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
(R)- 6-ethyl-8-fluoro-4-methyl -1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
(R)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
(R)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole;
(R)-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole-6-carbonitrile; and
(R)-4,6,10-trimethyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole.

33. A process for the preparation of a compound according to formula (I)



(I)

wherein

R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, hydroxy, alkyl, cycloalkyl, arylalkyl, aryl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, mono- and di-alkylaminocarbonyl, alkylcarbonylamino, carboxy and heterocyclyl, or R^3 and R^4 form together a $-CH_2-CH_2-CH_2-$ group;

with the proviso that at least one of R^1, R^2, R^3 and R^4 is not hydrogen;

R^5 is hydrogen, alkyl or cycloalkyl;

R^6 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl or alkoxyalkyl; and

R^7 is hydrogen, halogen, alkyl, cycloalkyl, hydroxyalkyl, carboxyalkyl, carbamoylalkyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, formyl, alkylcarbonyl, alkoxy or alkylthio;

comprising alkylation of a compound selected from the group consisting of

a)



wherein R^1, R^2, R^3, R^4, and R^7 are as defined above,

b)



E

wherein R^1, R^2, R^3, R^4, R^5, and R^7 are as defined above, and PG' is hydrogen or an OH-protecting group, and

c)



Z

wherein R^1, R^2, R^3, R^4, R^5, and R^7 are as defined above;

with a compound of formula (III)



(III)

wherein R^6 is as defined as above.

34. A pharmaceutical composition comprising a compound of formula (I) as set out in claim 1 and a pharmaceutically acceptable carrier or excipient.